6 unknown, 5 completed, 3 active not recruiting, 3 not yet recruiting. 5 Phase 3, 4 Phase 2, 2 Not applicable, 1 Phase 1.
Follow Nephrocalcinosis: new trials by email Literature Review of Nephrocalcinosis trials Research Report on Nephrocalcinosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Diagnostic Work-up of Nephrocalcinosis in Children Nephrocalcinosis | Not yet recruiting | Assiut University | 40 | 2026-10-20 | 2026-10-20 | |
| The GranStone Trial empagliflozin (Jardiance) 25 mg, Losartan 100 mg - Paraffinoma, Granuloma, Foreign-Body | Phase 2 / Phase 3 | Not yet recruiting | Martin Blomberg Jensen | 100 | 2026-09-01 | 2026-09-18 |
| Effect of Comprehensive Spa Care on Kidney and Urological Conditions: A Clinical Study in Adult Patients Comprehensive Spa Care, Exercise Therapy, Dietotherapy - Urologic Diseases, Urinary Tract Infections | Not applicable | Recruiting | Institute of Spa and Balneology, public research institution | 150 | 2026-04-07 | 2026-04-24 |
| Is CYP24A1 Heterozygosity a Risk Factor for Nephrolithiasis? Supplementary blood samples for PBMC analysis at V2 - Nephrolithiasis | Not yet recruiting | Hospices Civils de Lyon | 45 | 2025-12-01 | 2025-12-02 | |
| Effective Dosing of Burosumab in XLH X-linked Hypophosphatemia (XLH) | Recruiting | University of Nottingham | 120 | 2025-11-03 | 2026-05-11 | |
| Prevalence and Risk Factors of Nephrocalcinosis in Children at Sohag University Hospital Nephrocalcinosis | Unknown | Sohag University | 50 | 2023-06-01 | 2023-06-13 | |
| Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1 Encaleret, Standard of Care - Autosomal Dominant Hypocalcemia (ADH) | Phase 3 | Active not recruiting | Calcilytix Therapeutics, Inc., a BridgeBio company | 67 | 2023-01-06 | 2026-07-29 |
| ADH1 and ADH2 Disease Monitoring Study (DMS) Autosomal Dominant Hypocalcemia | Active not recruiting | Calcilytix Therapeutics, Inc., a BridgeBio company | 95 | 2022-01-20 | 2026-04-30 | |
| Epidemiology and Risk Factors of Nephrolithiasis and Nephrocalcinosis With Pediatric Onset Nephrocalcinosis | Enrolling by invitation | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | 800 | 2021-11-20 | 2026-10-14 | |
| Natural History of Patients With PH3 and a History of Stone Events Primary Hyperoxaluria Type 3 | Completed | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 7 | 2021-09-09 | 2024-12-02 | |
| Phenotyping of Primary Hyperoxaluria Primary Hyperoxaluria | Unknown | University Hospital, Strasbourg, France | 186 | 2021-01-22 | 2021-11-04 | |
| Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Fluconazole in Hypercalcicuric Patients With Increased 1.25(OH) 2D Levels Fluconazole, Placebo - Nephrolithiasis, Nephrocalcinosis | Phase 2 | Completed | Hospices Civils de Lyon | 56 | 2021-01-13 | 2024-07-12 |
| The Incidence and the Risk Factors of Nephrocalcinosis in Very Preterm Infants Nephrocalcinosis, Preterm Infant | Completed | Vilnius University | 171 | 2018-10-01 | 2021-12-23 | |
| Rifampin in CYP24A1-related Hypercalcemia and Hypercalciuria Rifampin - Idiopathic Infantile Hypercalcaemia - Severe Form, Genetic Disease | Phase 2 | Recruiting | Children's Hospital of Philadelphia | 60 | 2018-07-25 | 2026-10-13 |
| The Antibiotic Rifampin to Reduce High Levels of Blood and Urine Calcium in IIH Rifampin 150 mg, 300 mg capsules and 25 mg/mL oral suspension - Idiopathic Infantile Hypercalcemia - Mild Form | Phase 1 | Unknown | The Hospital for Sick Children | 5 | 2018-02-22 | 2021-08-31 |
| Preterm Infants and Nephrocalcinosis Prematurity, Nephrocalcinosis | Completed | University of Utah | 56 | 2015-04-01 | 2017-03-13 | |
| ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot Study ACTHAR Gel (adrenocorticotropic hormone) - Sarcoidosis, Hypercalcemia Due to Sarcoidosis | Phase 2 / Phase 3 | Unknown | Albany Medical College | 10 | 2015-02-01 | 2015-01-26 |
| Study to Assess the Efficacy and Safety of Oral Potassium Citrate on the Prevention of Nephrocalcinosis in Extreme Premature Potassium Citrate, Placebo - Nephrocalcinosis | Phase 3 | Unknown | Juan A. Arnaiz | 74 | 2013-01-01 | 2012-12-27 |
| Renal Tubular Acidosis in Incident Renal Transplant Recipients Renal Transplant Disorder | Unknown | Universitaire Ziekenhuizen KU Leuven | 50 | 2012-05-01 | 2012-05-30 | |
| Alkaline Citrate Treatment to Lower the Risk of Nephrocalcinosis in Preterm Infants Alkaline citrate - Nephrocalcinosis | Phase 3 | Completed | University of Cologne | 80 | 2005-11-01 | 2012-07-03 |
Showing 20 of 22. Sign in to see all of them.
Hypercalciuria (9) · Nephrolithiasis (7) · Hypercalcemia (4) · Hyperoxaluria, Primary (3) · Kidney Calculi (3) · Premature Birth (3) · Calcium Metabolism Disorders (2) · Hypercalciuric Hypocalcemia, Familial (2) · Hypocalcemia (2) · Hypoparathyroidism (2) · Metabolic Diseases (2) · Muscular Diseases (2) · Musculoskeletal Abnormalities (2) · Musculoskeletal Diseases (2)
Calcinosis (22) · Female Urogenital Diseases (22) · Female Urogenital Diseases and Pregnancy Complications (22) · Male Urogenital Diseases (22) · Nutritional and Metabolic Diseases (22) · Urogenital Diseases (22) · Kidney Diseases (21) · Urologic Diseases (21) · Calcium Metabolism Disorders (20) · Metabolic Diseases (20) · Pathological Conditions, Signs and Symptoms (13) · Signs and Symptoms (10) · Urolithiasis (10) · Urological Manifestations (10) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (9)
Rifampin (2) · Adrenocorticotropic Hormone (1) · Exercise Therapy (1) · Fluconazole (1) · Losartan (1) · Mud Therapy (1) · Potassium Citrate (1) · Sodium Chloride (1) · Standard of Care (1) · Suspensions (1) · Videotape Recording (1) · empagliflozin (1)
Calcilytix Therapeutics, Inc., a BridgeBio company (2) · Hospices Civils de Lyon (2) · Albany Medical College (1) · Assiut University (1) · Children's Hospital of Philadelphia (1) · Dicerna Pharmaceuticals, Inc., a Novo Nordisk company (1) · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico (1) · Indiana Kidney Stone Institute (1) · Institute of Spa and Balneology, public research institution (1) · Juan A. Arnaiz (1) · Martin Blomberg Jensen (1) · Mayo Clinic (1) · Sohag University (1) · The Hospital for Sick Children (1) · Universitaire Ziekenhuizen KU Leuven (1)
United States (8) · France (5) · Canada (4) · United Kingdom (4) · Denmark (3) · Germany (3) · Italy (3) · Australia (2) · Belgium (2) · Czechia (2) · Japan (2) · Netherlands (2) · Finland (1) · Lithuania (1) · Poland (1)
Ahlam B Ali, prof (1) · Bernd Hoppe, Prof. Dr. (1) · Etienne Sochett, MD (1) · Francisco Botet Mussons, MD (1) · James Law, BMBS, PhD, MRCPCH (1) · James Lingeman, MD (1) · John C Lieske, M.D. (1) · Marc A Judson, MD (1) · Martin B Jensen, Professor (1) · Michael A Levine, MD (1) · Pieter Evenepoel, MD (1) · Rasa Garunkstiene, PhD (1)
PMID 15961949, PMID 21956187, PMID 33461896, PMID 35710560, PMID 35925106
R01DK112955 (1)